Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “High-risk Plasma Cell Neoplasms”

Showing 20 of 0 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT05955508
What this trial is testing

A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma

Who this might be right for
Smoldering Multiple Myeloma (SMM)
Regeneron Pharmaceuticals 40
Testing effectiveness (Phase 2)Study completedNCT00148317
What this trial is testing

Phase II Study of Velcade, Decadron, and Doxil Followed by Cyclophosphamide in Multiple Myeloma

Who this might be right for
Multiple Myeloma
Weill Medical College of Cornell University 38
Testing effectiveness (Phase 2)Study completedNCT02597062
What this trial is testing

High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma

Who this might be right for
Multiple Myeloma
Canadian Cancer Trials Group 76
Not applicableLooking for participantsNCT06212323
What this trial is testing

Smoldering Myeloma High-Risk Patient Observation and Longitudinal Insight Trial

Who this might be right for
Smoldering Multiple Myeloma
University of Utah 100
Testing effectiveness (Phase 2)Study completedNCT01517724
What this trial is testing

Bortezomib Consolidation Trial

Who this might be right for
Multiple Myeloma
University College, London 40
Testing effectiveness (Phase 2)Active Not RecruitingNCT04933539
What this trial is testing

Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma

Who this might be right for
Multiple Myeloma
National Cancer Institute (NCI) 14
Testing effectiveness (Phase 2)Study completedNCT03490344
What this trial is testing

Short Course Daratumumab in Patients With Multiple Myeloma

Who this might be right for
Multiple Myeloma
Memorial Sloan Kettering Cancer Center 10
Testing effectiveness (Phase 2)WithdrawnNCT01531751
What this trial is testing

High Cut-off Hemodialysis in Patients With Advanced Cardiac AL Amyloidosis and End Stage Renal Disease

Who this might be right for
Primary Amyloidosis of Light Chain Type
Fondazione IRCCS Policlinico San Matteo di Pavia
Large-scale testing (Phase 3)WithdrawnNCT07428369
What this trial is testing

Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM)

Who this might be right for
Multiple Myeloma (MM)
Regeneron Pharmaceuticals
Early research (Phase 1)Study completedNCT02697383
What this trial is testing

Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot Study

Who this might be right for
Multiple MyelomaHigh Risk Smoldering Multiple Myeloma
Memorial Sloan Kettering Cancer Center 14
Testing effectiveness (Phase 2)Ended earlyNCT03850522
What this trial is testing

PD-L1 Peptide Vaccination in High Risk Smoldering Multiple Myeloma

Who this might be right for
Smoldering Multiple Myeloma
Lene Meldgaard Knudsen 6
Testing effectiveness (Phase 2)Study completedNCT00003658
What this trial is testing

Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Other B-cell Cancers

Who this might be right for
LeukemiaLymphoma
Memorial Sloan Kettering Cancer Center 60
Testing effectiveness (Phase 2)Ended earlyNCT02573935
What this trial is testing

Clarithromycin in Multiple Myeloma Induction Therapy

Who this might be right for
Multiple Myeloma
Henrik Gregersen 58
Early research (Phase 1)Study completedNCT00004904
What this trial is testing

Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Who this might be right for
Chronic Myeloproliferative DisordersGraft Versus Host DiseaseLeukemia+5 more
Northwestern University
Large-scale testing (Phase 3)Study completedNCT00205764
What this trial is testing

Tandem High Dose Melphalan Versus Triple Intermediate Dose Melphalan and Stem Cell Transplantation in Induction Phase and Prednisolone/IFN Versus IFN in Maintenance Therapy

Who this might be right for
Multiple Myeloma
Austrian Forum Against Cancer 212
Large-scale testing (Phase 3)Study completedNCT02288741
What this trial is testing

Tandem Melphalan and Autolog. SCT in MM Patients 60 to 70 Years of Age With and Without Induction Chemotherapy

Who this might be right for
Multiple Myeloma
WiSP Wissenschaftlicher Service Pharma GmbH 549
Early research (Phase 1)Active Not RecruitingNCT03549442
What this trial is testing

Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma

Who this might be right for
Multiple Myeloma
University of Pennsylvania 40
Testing effectiveness (Phase 2)Study completedNCT00335647
What this trial is testing

Fluphenazine in Treating Patients With Refractory Advanced Multiple Myeloma

Who this might be right for
Multiple Myeloma and Plasma Cell Neoplasm
Immune Control 30
Testing effectiveness (Phase 2)Study completedNCT01242267
What this trial is testing

Escalating Doses of Thalidomide in Conjunction With Bortezomib and HIgh Dose Melphalan for BSCT

Who this might be right for
Multiple Myeloma
Hackensack Meridian Health 29
Testing effectiveness (Phase 2)WithdrawnNCT03785184
What this trial is testing

Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy

Who this might be right for
Multiple Myeloma
AbbVie
Next Page

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation